Delving into the Latest Updates on Curon Biopharmaceutical Ltd. with Synapse

Overview

Basic Info

Introduction

Tongrun Biomedicine (Shanghai) Co Ltd. is a Shanghai-based company with branches in Hong Kong. It specializes in the development of cancer immunotherapies and was established by Paul Song. According to the company, it was founded in June 2018 and focuses on creating next-generation anti-cancer treatments. The company is headed by a highly experienced international executive team and has several promising novel cancer a agents in its pipeline. Tongrun Biopharmaceutical is dedicated to bringing the next generation of cancer immunotherapies to patients and aims to accelerate the clinical development of its pipeline assets. Additionally, the company plans to expand its portfolio through collaborations with biotech and pharmaceutical companies worldwide to provide more effective treatment options for patients.

Tags

Hemic and Lymphatic Diseases

Neoplasms

Immune System Diseases

Bispecific T-cell Engager (BiTE)

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Hemic and Lymphatic Diseases	3
Neoplasms	3
Immune System Diseases	3

Top 5 Drug Type	Count

Bispecific T-cell Engager (BiTE)	2
Small molecule drug	1
Unknown	1

Top 5 Target	Count

CD19 x CD3(B-lymphocyte antigen CD19 x T cell surface glycoprotein CD3)	2
PI3Kγ x PI3Kδ(Phosphatidylinositol-4,5-Bisphosphate 3 kinase gamma x Phosphatidylinositol 3 kinase delta)	1

主要目的：Ib期：评估CN201的安全性和耐受性；评估CN201的剂量限制性毒性（DLT）和最大耐受剂量（MTD）；确定CN201的II期推荐剂量（RP2D）。II期：评估CN201治疗复发或难治的B-ALL患者的抗白血病疗效。次要研究目的：Ib期：评估CN201在B-ALL患者体内的PK特征；评估CN201在B-ALL患者体内的药效动力学特征；评估CN201的免疫原性；评估CN201的抗白血病活性。II期：进一步评估CN201的安全性和耐受性；进一步评估CN201在患者体内的PK特征；进一步评估CN201在患者体内的药效动力学特征；进一步评估CN201的免疫原性；进一步评估CN201在复发或难治的B-ALL患者中的抗白血病活性。

[Translation]

Primary objectives: Phase Ib: Evaluate the safety and tolerability of CN201; Evaluate the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of CN201; Determine the Phase II recommended dose (RP2D) of CN201. Phase II: Evaluate the anti-leukemic efficacy of CN201 in patients with relapsed or refractory B-ALL. Secondary study objectives: Phase Ib: Evaluate the PK characteristics of CN201 in patients with B-ALL; Evaluate the pharmacodynamic characteristics of CN201 in patients with B-ALL; Evaluate the immunogenicity of CN201; Evaluate the anti-leukemic activity of CN201. Phase II: Further evaluate the safety and tolerability of CN201; Further evaluate the PK characteristics of CN201 in patients; Further evaluate the pharmacodynamic characteristics of CN201 in patients; Further evaluate the immunogenicity of CN201; Further evaluate the anti-leukemic activity of CN201 in patients with relapsed or refractory B-ALL.

Start Date01 Nov 2022

Sponsor / Collaborator

Curon Biopharmaceutical Ltd.

NCT05579132 / RecruitingPhase 1/2

An Open-label, Multi-center Phase Ib/II Study of CN201 in Subjects With Precursor B-cell Acute Lymphoblastic Leukemia

An effective treatment for adults and children B-ALL represents a significant unmet need. CN201 has demonstrated efficacy in nonclinical models of leukemia .CN201 has a longer half-life, thus long term continuous intravenous infusion is not necessary for clinical use. The present study will be conducted in 2 parts: Phase Ib is a dose finding phase to identify the RP2D. Phase II will allow further evaluation of the safety and efficacy of CN201 at the RP2D.

Start Date30 Sep 2022

Sponsor / Collaborator

Curon Biopharmaceutical (Hong Kong) Ltd.

NCT05028478 / Unknown statusPhase 1/2

An Open-Label, Multi-center, Phase I/II Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

The study is designed to evaluate the safety, tolerability, pharmacokinetic characteristics and anti-tumor activity of CN202 in adult subjects with locally advanced or metastatic solid tumor or hematologic malignancies

Start Date22 Oct 2021

Sponsor / Collaborator

Curon Biopharmaceutical Ltd.

[+1]

100 Clinical Results associated with Curon Biopharmaceutical Ltd.

Login to view more data

0 Patents (Medical) associated with Curon Biopharmaceutical Ltd.

Login to view more data

1

Literatures (Medical) associated with Curon Biopharmaceutical Ltd.

Protein drug-drug interactions for therapeutic modalities

Author: Montgomery, Diana ; Liu, Liming ; Evers, Raymond

A review.In this chapter, we focus on the major mechanisms of therapeutic protein-drug-drug interactions (TP-DDI).We discuss the potential DDI between small mols. and protein drugs, between two different TPs and potentialinteractions between known and emerging therapeutic modalities.Based on TP-DDI risk, clin. design considerations are also discussed.

100 Deals associated with Curon Biopharmaceutical Ltd.

Login to view more data

100 Translational Medicine associated with Curon Biopharmaceutical Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 05 Jul 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

Preclinical

Phase 2

2

3

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

CN-201 ( CD19 x CD3 )	B-cell lymphoma recurrent More	Phase 1
anti-CD3/CD19 bispecific antibody ( Curon Biopharmaceutical ) ( CD19 x CD3 )	Acute Lymphoblastic Leukemia More	Discovery
CN-401 ( PI3Kγ x PI3Kδ )	Lymphoma More	Discontinued
CN1 ( Cytokines )	Solid tumor More	Pending
CN-202 ( PDL1 x TGF-β )	Hematologic Neoplasms More	Pending